Abstract LB036: Characterization of BLU-448: A potent and selective degrader of CDK4 for the treatment of HR+/HER2- breast cancers
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Zhihu (Jeff) Ding, Xiang Liu, Barbara K. Robens, Jeff Keats, Suzanne Spong, Fereidoon Daryaee, Michael R. Wasserman, Benjamin Barlock, Jian Guo, James Baker, Kenneth Kearney, Gramoz Kondakci, Camila Medrano-Trochez, Christophe Lemetre, Emily Erickson, Hana von der Linden, Dean Zhang, Sheng Sun, Rentian Wu, Lakshimi Muthuswamy, Jie Ge, Luis Torres, Kevin Barvian, Thiwanka Mudiyanselage, Winston L. Chow, Deborah G. Conrady, Yunxing (Stella) Li, Xavier Fradera, Yinghui Dai, Caitlin Kinkema, Jason Brubaker, Robert Meissner, Thomas A. Dineen, Chiara Conti, Kerrie Faia, Scott Ribich
Institution: Blueprint Medicines (United States)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: closed
OpenAlex ID: W7154744990
Cites:
Cited by:
Related to: